Quantcast

Latest Sunitinib Stories

2006-06-03 13:00:00

By Ransdell Pierson NEW YORK -- A Pfizer Inc. kidney cancer drug has also shown promise in a small mid-stage trial as a treatment for the most common form of lung cancer, researchers said on Saturday. The new study involved 63 patients whose non-small cell lung cancer had progressed despite earlier treatments with standard chemotherapy. All patients were then given Pfizer's once-daily pill, Sutent, as a stand-alone treatment and continued to take it until their disease progressed. Tumors...

2005-12-21 09:44:55

By Susan Heavey WASHINGTON (Reuters) - The U.S. Food and Drug Administration approved a new drug to treat the most common type of kidney cancer on Tuesday, hailing it as a major advance in slowing tumor growth. The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., helped curb the size and number of tumors, although it has not yet been shown to help patients live longer, the FDA said. It is the first drug approved to treat advanced kidney cancer since...

2005-12-20 18:46:48

By Susan Heavey WASHINGTON (Reuters) - The U.S. Food and Drug Administration approved a new drug to treat the most common type of kidney cancer on Tuesday, hailing it as a major advance in slowing tumor growth. The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., helped curb the size and number of tumors, although it has not yet been shown to help patients live longer, the FDA said. It is the first drug approved to treat advanced kidney cancer since...

2005-11-03 14:47:04

Paris, France, Thursday 3 November 2005 - Updated results from a Phase III trial presented at the 13th European Cancer Conference (ECCO) show that sunitinib (SU11248) prolongs both progression-free and overall survival in patients with progressive metastatic and/or unresectable GIST whose disease has failed to respond to the standard therapy - imatinib mesylate. This study was a double-blind, placebo-controlled, international, multicentre, Phase III trial involving 312 patients with GIST...

2005-09-08 08:06:36

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON, Sept 8 - Pfizer Inc is ready to launch a patient-monitoring scheme to assess the safety of its novel inhaled-insulin drug Exubera if the product is approved for use, its worldwide head of development said on Thursday. Exubera is being developed with Sanofi-Aventis SA and Nektar Therapeutics, and is due to be reviewed by a U.S. Food and Drug Administration (FDA) panel later on Thursday. Most industry analysts expect a...

2004-11-30 15:00:10

GROTON, Conn., Nov. 30 /PRNewswire-FirstCall/ -- Pfizer Inc said today it is on track to achieve its goal of submitting 20 New Drug Application (NDA) filings in the five-year period ending in 2006, reflecting the industry's premier research and development pipeline. In a presentation to financial analysts at the company's largest research and development site, Pfizer said it will have completed 12 of these 20 regulatory filings by the end of 2004. Pfizer also announced that its drug...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related